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Abstract.  CD44 is a  family of glycoproteins involved 
in cell-cell and cell-matrix interactions.  In addition to 
the major 90-kD form present on most hematopoietic 
cells, larger  140-230 kD forms are found on keratino- 
cytes and carcinoma cell lines.  These bigger isoforms 
of CD44 arise by alternative  splicing that results in in- 
sertion of one or more of the "variant" exons into the 
extracellular part of the 90-kD constant form of the 
molecule.  In rat,  v6 (variant exon v6) containing  form 
of CD44 confers metastatic potential to carcinoma 
cells, and therefore,  it is of interest to study the distri- 
bution of this isoform in humans.  We raised antibodies 
against a synthetic peptide containing  a  sequence en- 
coded by the exon v6. A  mAb thus obtained (desig- 
nated Var3.1) strongly reacted with the plasma mem- 
branes of squamous cells in upper layers of skin and 
tonsil surface epithelia.  Weaker staining was seen in 
germinal centers, vascular endothelia and enterocytes. 
Exon v6 containing  forms of CD44 (CIM4v6) were 
absent from tissue leukocytes and connective tissue 
components.  In comparison,  Hermes-3 epitope (on the 
constant part) containing  forms of CD44 were prefer- 
entially localized in basal layers of epithelia,  present 
on the surface on most leukocytes and connective tis- 
sue cells, and undetectable on the luminal  surface of 
high endothelial venules. In benign neoplasms,  epithe- 
lial cells stained with mAb Var3.1 like in normal tis- 
sues. In contrast,  immunostaining  of 30 squamous 
carcinoma specimens (both primary and metastatic le- 
sions) revealed that malignant transformation  resulted 
in downregulation or disappearance of Var3.1 epitope, 
but in majority of cases, not in diminished  synthesis 
of the Hermes-3 epitope. Biochemical analyses showed 
that mAb Var3.1 recognized two major forms of CD44 
(220 and 300 kD).  In conclusion, epitopes on exon v6 
and constant part of CD44 are differentially synthe- 
sized and regulated during normal and malignant 
growth of cells in man. 
C 
ELL-cell  and cell-matrix interactions  are of funda- 
mental  importance  to  multicellular  organisms  in 
controlling  organized  growth,  differentiation,  and 
migration  of cells.  CD44 is one of the molecules known to 
be involved in these adhesion-dependent  processes. In man, 
it was independently  discovered by several groups using anti- 
bodies against molecules referred to as brain-granulocyte-T 
lymphocyte antigen,  human medullary thymocyte antigen, 
Lutheran inhibitor related antigen,  p85,  phagocytic  glyco- 
protein-l,  Hermes-antigen,  extracellular  matrix  receptor 
type III, and hyaluronate  receptor (5, 7,  16, 23, 28, 36, 55, 
56). Later, these antibodies have been shown to identify the 
same CD44 cluster (6,  10, 41, 44).  CD44 is a multifunc- 
tional  glycoprotein (for review  see references  17,  18) in- 
volved at least in lymphocyte-endothelial cell interactions 
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(26, 28, 42, 43), adhesion  of cells to extracellular  matrix 
proteins  (2,  5,  27,  40,  56),  lymphohematopoiesis  (39), 
homotypic adhesion  (3, 51), T cell activation and adherence 
(1, 8, 15, 22, 32, 45, 48, 49), cytokine release (57), metasta- 
sis  formation  (see below), and  lateral  movement of cells 
(25).  CD44 is widely distributed on several hematopoietic 
and nonhematopoietic cells including  all subsets of leuko- 
cytes, erythrocytes, many types of epithelium,  mesenchymal 
elements like fibroblasts and smooth muscle cells, and glial 
cells of the central nervous system (5, 7, 16, 23, 36, 37, 43, 
55).  Most hematopoietic cells,  fibroblasts,  and  glial  cells 
predominantly  express a 90-kD form of CD44. At least lym- 
phocytes also have a minor 180-kD form which represents 
a chondroitin  sulfate  modification  of the 90-kD backbone 
(29). In contrast, CD44 antigen in epithelial cell lines is con- 
siderably larger (140-160 kD), and still larger  forms up to 
230-kD have been described (4, 41, 43). Recently, the mo- 
lecular basis of these biochemically distinct forms has been 
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lymphoid lines revealed an integral membrane glycoprotein, 
which has an NH2-terminal extracellular region, short hy- 
drophobic transmembrane  region,  and  a  cytoplasmic tail 
(12, 52). Later, an epithelial 150-kD form was cloned from 
keratinocytes and carcinoma cell lines (4, 53). It contains an 
additional stretch of 132 amino acids inserted in the mem- 
brane proximal part of the common peptide backbone. Forms 
containing the same sequence or a shorter part of it were also 
found in hematopoietic cells (9). In the rat, and subsequently 
in man, altogether five extra "domains" of CD44 have been 
identified (13, 20,  24, 33). More recently, these "domains" 
have been reported to be comprised of at least ten distinct 
exons named vl-vl0 (1). Finally, genomic cloning revealed 
that human CD44 contains at least 19 exons, 12 of which can 
be alternatively spliced (47).  CD44 molecules containing 
one or more (in different combinations) of  these alternatively 
spliced exons within the common backbone are designated 
as variant forms to distinguish them from the major 90-kD 
lymphocyte form (standard). In this paper, we will use the 
term exon v6 (the sixth variant exon of CD44) that corre- 
sponds to nucleotides 1140-1267 of the largest known form 
of human CD44 eDNA (20), and to the tenth exon in the 
genomic structure of  CD44 (47). Exon v6 together with exon 
v7 (nucleotides 1268-1397 in Ref. 20) form the structure that 
has formerly been called domain 3 of CD44 (13).  For sim- 
plicity, the term exon v6 will be used to refer both to the 
DNA sequence of exon v6 and to the protein that it encodes. 
CD44 isoforms play important and distinct roles in tumor 
metastasis.  The standard 90-kD  lymphocyte form appar- 
ently contributes to the metastatic capacity of non-Hodgkin 
lymphomas in man (21, 30). The lymphocyte form, but not 
the  150-kD epithelial form (containing exons v8-10), also 
enhances local tumor formation and metastatic proclivity of 
transfected lymphoma cells in a nude mouse model (54). On 
the other hand, expression of the epithelial form is increased 
in carcinoma cell lines, which may suggest a role for the 150- 
kD  molecule in tissue invasiveness (52).  Finally,  in a  rat 
model,  exon  v6  has  been  reported  to  confer metastatic 
potential to rat adenocarcinoma cells (13).  In man, specific 
analysis of the expression pattern of these variant forms has 
been limited to the RNA level in cell lines (20) since there 
has been no mAbs available that can distinguish between the 
standard and variant CD44. It is currently not known what 
kind of tissue distribution the variant forms exhibit in man 
and whether they are expressed on the cell surface. More- 
over, it is not clear how expression of different isoforms is 
regulated during normal cell differentiation and what kind of 
changes take place in malignant transformation. 
To address these questions,  we produced mAbs  against 
exon v6 of  the human variant CD44. Distribution of  the exon 
v6 containing forms of CD44 (CD44v6)~  in normal tissues 
and tumors was determined, and compared to that of the 
forms  recognized by  mAb  Hermes-3.  Also,  biochemical 
properties of CD44v6 were analyzed. The results may be 
helpful  in  understanding  the  biological  role  of CD44v6 
in man. 
1. Abbreviation(s)  used in this paper:  CD44v6, exon v6 containing fi~rms 
of CD44; IPTG, isopropyl/3-D-thiogalactopyranoside; pGEX-2T-Var, plas- 
mid GEX-2T with exon v6 containing insert. 
Materials and Methods 
Production of mAb against Human Exon v6 
of Variant CD44 
A synthetic peptide representing a  16-amino acid sequence from the exon 
v6 of the human variant CD44 (STTEETATQKEQWFGN, ref 20; an addi- 
tional COOH-terminal cysteine was included for coupling purposes) was 
prepared using an automated peptide synthesizer (model 431 A, Appl. Bio- 
systems Inc., Foster City, CA). Purification of the peptide was carded out 
with a preparative HPLC (Appl. Biosystems Inc.) using a  reverse phase 
column and its purity was confirmed by an analytical HPLC. The peptide 
was also independently sequenced (model 477A  equipped with an online 
PTH amino acid analyzer 120A, Appl. Biosystems Inc.) and analyzed with 
resorption time-off-flight mass analyzer (BioIon  r~m Biopelymer Mass An- 
alyzer, Appl. Biosystems) and found to be correct. One hundred microgram 
peptide in incomplete Freund's adjuvant was injected into the footpads of 
specific pathogen free Balb/c mice three times at one week intervals. After 
sacrificing, lympbocytes from popliteal lymph nodes were isolated and 
fused with NS-1 myeloma cells using standard procedures. Hybridoma su- 
pernatants were tested in ELISA (see below) using the synthetic peptide as 
an antigen and a  positive hybridoma (designated Var3.1) was subcloned 
twice by limiting dilution. The isotype of mAb Var3.1 is Ig G1. 
Production of anti-CD44 mAbs of Hermes-series has been described 
(26). Hermes-3 recognizes an epitope in the proximal extracellular part of 
the constant region of CD44  (12).  3G6 and  llG2,  mouse mAbs against 
chicken T cells, were used as negative controls. All antibodies were used 
as serum-free supernatants or as (NH4)zSO4 precipitated concentrates. 
ELISA 
The synthetic peptide from the exon v6 (STTEETATQKEQWFGN-C) and 
control peptides (TQSEAWTFTQENKTEG,  a  scrambled version of the 
exon v6 specific peptide and DELPQVTLPHPNLHGPEILDVPST, an ir- 
relevant peptide) were absorbed to the bottom of microtiter wells (Dynatech 
Labs. Inc., Chantilly, VA) overnight at 37°C (10 pg/well). After washings, 
the remaining binding sites were blocked with 1% gelatin, and after wash- 
ings the primary antibodies were added for 2 h. Alkaline phosphatase-con- 
jugated goat anti-mouse IgG and IgM (Tago, Inc., Burlingame, CA) was 
used as the second stage antibody, and p-nitropheoylphosphate as the sub- 
strate. Absorbances were read in Multiscan (Labsystems, Helsinki, Fin- 
land) at 405 nm. 
Construction and Analysis of  pGEX-2T-fusion Proteins 
Containing Exon v6 of  Human Variant  CD44 
Exon v6 containing form of CD44 was amplified from HaCaT cells by re- 
verse transcriptase PCR and cloned into pGEX-2T vector (50)  for fusion 
protein production.  HaCaT  RNA was isolated by the guanidine isothio- 
cyanate-phenol extraction method. First strand eDNA synthesis  was carded 
out using 1.5 pg total RNA, oligo(dT) primer, and M-MLV reverse tran- 
scriptase according to the instructions of the manufacturer (Perkin Elmer 
Cetus, Norwalk, CT). Because HaCaT cells have several forms of CD44 
(data not shown), existence of v6 in the PCR product was ensured by using 
two sets of  primers in two separate PCR amplification reactions as schemati- 
cally illustrated in Fig. 2 A. In one reaction (Ia), primers A and B were used 
and in the other reaction (lb), primers C and D were employed. Thereafter, 
the products were combined in a reaction (II) using primers E and F which 
contained BamH1  and EcoR1 tails, respectively. The presence of exon v6 
in the 0.95-kb PCR product was confirmed by DNA sequencing. 
The 0.95-kb fragment (including variant exons v6-10) was isolated from 
1.5% agarose gel, digested with BamH1  and EcoRl, and ligated using T4 
ligase (Stratagene, La JoUa, CA) into pGEX-2T expression vector (46, 50). 
Hereafter, the plasmid pGEX-2T with the 0.95-kb v6 containing insert is 
called pGEX-2T-Var. Bacteria (E. coli DH5ot strain) were transformed with 
pGEX-2T-Var using CaCi2  method. Production of fusion protein was in- 
duced with isopropyl/3-D-thiogalactopyranoside  (IP'II3) for 4 h, after which 
bacteria were pelleted and lysed in Laemmli's sample buffer containing 2 % 
SDS. Samples from whole cell lysates of pGEX-2T-Var and pGEX-2T (con- 
trol) transformants were run using a 5-12.5%  SDS-PAGE. After electro- 
phoresis,  the  proteins  were transferred onto  nitrocellulose membranes 
(Schleicher-Schuell, Dassel, Germany) by blotting 1.5 h at 1A in a Trans- 
pbor apparatus (Hoefer Sci. Instrs., San Francisco, CA). The membranes 
were then soaked for 48 h in PBS containing 0.1% Tween-20 and 1% non-fat 
milk powder. After washings in PBS, membranes were cut into strips and 
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tion in PBS containing peroxidase-conjugated  rabbit anti-mouse Ig (Dako- 
patt A/S, Glostrup, Denmark) was performed. After extensive washing, the 
membranes were developed in PBS containing 16% methanol, 0.5 mg/ml 
4-chloro-l-naphthol (Sigma Chem. Co., St. Louis, MO) and 0.01% hydro- 
gen peroxide.  Same amount of samples were also run on parallel gels which 
were subsequently fixed in 40% methanol and 10% acetic acid, and stained 
with Coomassie brilliant blue.  Alternatively,  after IPTG induction and 
pelleting, the bacteria were resuspended in PBS containing 1%  NP-40, 
10 mM EDTA,  1 mM PMSF, and 1% aprotinin. Cells were lysed by three 
cycles of freezing and thawing. After centrifugation, supernatants were col- 
lected and added to glutathione-agarose beads (Glutathione Sepharose 4B, 
Pharmacia, Uppsala, Sweden) that were preequilibrated in the lysis buffer. 
After a  10-rain incubation at room temperature, beads were washed three 
times with PBS and once with washing buffer (50 mM Tris-HCl, pH 7.5, 
150  mM  NaC1),  and resnspended in thrombin cleavage  buffer  (3  mM 
CaCI2 in washing buffer).  Thrombin (from human plasma, Sigma Chem. 
Co.) was  added for 2  h  at room temperature.  Thereafter, samples were 
resolved in SDS-PAGE  and blotted onto Hybond-C Super nitrocellulose 
membrane (Amersham Intl., Buckinghamshire, England) using Trans-Blot 
SD semi-dry electrophoretic transfer cell (Bio-Rad  Labs., Hercules,  CA) 
and Bjerrum and Schafer-Nielsen transfer buffer (48 mM Tris, 39 mM gly- 
cine, 20% methanol, pH 9.2).  The membrane was blocked in PBS con- 
taining 10% non-fat milk powder and 0.3% Tween-20 for 1 h at room tem- 
perature. Immunodetection was done using enhanced chemiluminescence 
system (ECL Western blotting detection system, Amersham Intl.) according 
to  the  instructions of the manufacturer,  peroxidase-conjugated  affinity- 
purified anti-mouse Ig (Amersham Intl.) was used as the second-stage  re- 
agent. Light emission was detected with Hyperfilm-ECL (Amersham Intl.). 
Purification of CD44 and Western Blotting 
PBL from leukopheresis samples of patients suffering from rheumatoid ar- 
thritis were used for CIM4 antigen isolation as previously described (27). 
Briefly, lymphocytes (25-ml packed cells) were lysed in lysis buffer (1% NP- 
40, 0.15 M NaCI, 0.01 M Tris,  1.5 mM MgC12, and 1 mM PMSE pH 7.0). 
The clarified lysate was applied first to a Sepharose  CL-4B (Pharmacia) 
column, and then sequentially to three CnBr-activated Sepharose-4B (Phar- 
macia) columns derivatized with normal mouse serum, with irrelevant mAb 
and with Hermes-3 mAb (5 mg/ml, 3 ml column volume). The column was 
washed extensively with the lysis buffer. Thereafter, the material bound to 
the Hermes-3 column was eluted with 50 mM triethylamine and lyophil- 
ized. Isolated CD44 was subjected to SDS-PAGE and blotting as described 
above for fusion proteins with the exception that membranes were blocked 
in 0.1% Tween-20 for 3 h and 5% AB-serum (Finnish Red Cross, Helsinki, 
Finland) was added with the second-stage antibody. 
lmmunohistochemistry and 
Immunoelectronmicroscopy 
Tissue distribution  of the different forms of CIM4 was determined using im- 
munoperoxidase staining.  Surgical and skin punch biopsy specimens were 
snap frozen in liquid nitrogen.  Five #m frozen sections were cut, air-dried, 
and acetone fixed.  Sections  were overlaid with mAb supernatants and in- 
cubated for 30 min at room temperature in a humidified chamber. After two 
washings in PBS, peroxidase-conjngated  rabbit anti-mouse Ig in PBS con- 
taining 5% AB-sernm was added.  Finally, the reaction was developed  by 
adding 3,3-diaminobenzidine (Folysciences,  Inc., Warrington, PA) in PBS 
containing 0.03 % hydrogen peroxide for 3 min. After staining, the sections 
were  counterstained  in  hematoxylin  (Sigma  Chem.  Co.),  dehydrated, 
cleared in xylene, and permanently mounted in DePex  (BDH Limited, 
Pool, Dorset, England). 
FOr immunoelectronmicroscopy,  samples from human tonsils were snap- 
frozen in freon 22 chilled with liquid nitrogen. About 5-#m frozen sections 
were stained immediately using sequential  incubations with mAb Var3.1, 
biotinylated horse anti-mouse Ig, and avidin DH-biotinylated horseradish 
peroxidase H complex (Vectastain  ABC Kit;  Vector  Labs., Burllngame, 
CA). The reactions were followed by fixation in phosphate buffered 2 % glu- 
taraldehyde. Thereafter,  a representative section was examined light micro- 
scopically,  and an appropriate area was selected.  The corresponding area 
in parallel  sections was  trimmed,  sections were postfixed  in phosphate 
buffered 2% osmium tetroxide,  dehydrated, and embedded in epon at the 
open end of an inverted BEEM capsule.  Thin sections were double-stained 
with uranyl acetate and lead citrate, and then examined in a JEM 100 elec- 
tron microscope.  Slides processed without the primary or secondary anti- 
body,  with and without the double staining, served as controls. 
Cells and Cell Lines 
Human  PBL were isolated from healthy adult volunteers  using Ficoli- 
gradient (Ficoll-Hypaque,  Pharmacia)  centrifugation.  PBL were used fresh, 
or to obtain activated blast cells,  stimulated  with combination of 10 #g/rnl 
PHA and 1:100 PWM (GIBCO, BRL, Gaithersburg, MD) for 3 d at 37°C 
in  RPMI  1640  (GIBCO  BRL)  supplemented with  10%  FCS,  4  mM 
L-glutamine,  10 mM Hepes, 1 mM sodium pyruvate, penicillin (100 U/ml), 
and streptomycin (100/tg/ml). Human cell lines HeLa (epithelioid  carci- 
noma),  KG-I,  KG-Ia,  K-562,  U937 (leukemic  cells),  A549 0ung carci- 
noma), Tera-1 (HTB 105, embryonai carcinoma), and T-47 D (HTB 133, 
ductal carcinoma of breast) were obtained from American Type Culture 
Collection (Rockville,  MD). U1690 (human lung carcinoma cell line) was 
a kind gift from Dr.  H. Hirvonen (Department of Medical Biochemistry, 
Turku University, Finland) and HaCaT, a spontaneously immortalized non- 
tumorigenic keratinocyte line, was a kind gift from Professor N. E. Fusenig 
(German Cancer Research Center,  Heidelberg,  Germany). All cell lines 
were cultured in Dulbecco's  modified  minimal essential  medium (GIBCO 
BRL) supplemented with 10% FCS,  10 mM Hepes,  and antibiotics.  Ad- 
herent cells were passaged  using trypsin-EDTA  (Boehringer-Mannheim, 
Germany). 
lmmunofluorescence Staining 
Blood cells and adherent cell lines (detached with 5 mM EDTA in Ca  2+, 
Mg2+-free HBSS) were stained in suspension.  Cells were stained unfixed 
or after fixation and permeabilization (1% formaldehyde  in PBS (10 min) 
followed by  -200C acetone (5 min) followed by two washings  in PBS). 
Cells were incubated with primary antibodies for 20 rain at 4°C and washed 
twice in PBS containing 5 % FCS and 1 mM sodium azide.  Next, FITC- 
conjugated sheep anti-mouse IgG (Sigma Chem. Co.) in PBS containing 
5%  human AB-serum was added for 20 min. Thereafter,  the cells were 
washed twice and fixed in PBS containing 1% formaldehyde. Analyses were 
done using a FACScan cytometer (Becton Dickinson, Mountain View, CA). 
For immunofluorescence  microscopy, cells were spun on microscopic slides 
with Cytospin 2 cytocentrifuge  (Shandon Southern, Surrey, England) and 
mounted in glycerol  containing 10%  PBS.  Alternatively,  adherent cells 
were grown on glass coverslips, and processed without detachment for im- 
munofluorescence  microscopy  as described above. 
When studying the detergent resistance of Var3.1 and Hermes-3 epitopes, 
HaCaT cells grown on glass slides and cytocentrifuge  preparations of PBL 
were used.  Cells were first fixed and permeabilized as described above. 
Thereafter,  cells were incubated in PBS with or without 0.5%  NP-40 for 
5  min at 4"C and washed  twice.  Next,  the cells were  stained for im- 
munofluorescence  as described above, and analyzed using fluorescence mi- 
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Figure 1. mAb Var3.1 is specific for human exon v6 of CD44. Bind- 
ing of mAbs Var3.1,  Hermes-3,  and negative controls (3G6 and 
11G2) to v6 specific peptide (STrEETATQKEQWFGN),  and ei- 
ther to  an  irrelevant peptide  (DELPQVTLPHPNLHGPEILDV- 
PST,  Expts.  I  and I/)  or to  a  scrambled version of v6  specific 
peptide  (TQSEAWTFTQENKTEG,  Expt.  III)  was  determined. 
Results are presented as net absorbances (mean -t- SD) from tripli- 
cate samples of three independent ELISA experiments (net absor- 
bance =  absorbance to v6 specific peptide-absorbance to control 
peptide). 
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nizes  recombinant  proteins 
carrying exon v6.  (,4) Sche- 
matic  representation  of  the 
PCR strategy used to amplify 
CD44v6  from  HaCat  cells 
(see text for details). Box rep- 
resents  the  variant  part  of 
CIM4  and  exons  v6  and  v'/ 
are highlighted as a darkened 
area. Primers were as follows: 
A, 5' CAATTACCATAAC- 
TATTGTTAACCG 3'; B, 5' 
AATCAGTCCAGGAACT- 
GTCCT  3';  C, 5' GGCAA- 
CAGATGC~ATGAGCK3 3'; 
D, 5' AGTGGTATGGGAC- 
CCCCCACT~  3'; F, 5' 
ATAGGATCCAACCGTG- 
ATGC~ACCCGCT 3'; F, 5' 
TATGAATTCGGAATGT- 
GIL'TIGffIE'~ 3' Probe G: 
5' GCTGTCCCTGTTGTC- 
GAATG 3'. Numbering of nu- 
cleotides is based on data pre- 
sented  in  references  19,  20, 
52. (B) Coomassie blue stain- 
ing of the whole cell lysates 
of transformed bacteria after 
IFIG induction.  (Lane/) Cells 
transformed  with  pGEX-2T 
(a~:  the '~28-kD prod- 
uct of the parent vector); (lane 
2)  cells  transformed  with 
pGEX-2T-Var  (arrow:  the 
,'~60-kD  fusion protein con- 
taining v6). (C) Immunoblot- 
ting  of  the  same  lysates. 
Whole cell lysates of IPTG- 
induced bacteria transformed 
with  pGEX-2T-Var  (lanes  1 
and  3)  and  with  pGEX-2T 
(lanes 2  and 4) were stained 
with mAbs Vat3.1 (lanes I and 
2) and 3G6 (negative control, 
lanes 3  and  4).  mAb Var3.1 
stains the ,~60-kD fusion pro- 
tein (lane 1, arrow) but not the 
product of pGEX-2T (lane 2). Both mAbs nonspecificaily reacted with a  ,~38-kD molecule. (D) Immunoblottittg of the purified fusion 
protein. Affinity-purified  fusion protein from IPTG-induced bacteria transformed with pGEX-2T-Var was cleaved with thrombin before im- 
munoblotting, mAb Var3.1 (lane/) but not 11(32 (lane 2) stains the v6 containing 33-kD cleavage product. The less prominent •60-kD 
mAb Var3.1-reactive  band represents uncleaved fusion protein. M~, molecular weight standards in kD. 
croscopy. Similar results were obtained, when the cells were first stained 
and thereafter treated with the detergent. 
PCR Amplification of  Lymphocyte v6 
Total RNA was isolated from PBL obtained from blood donors and from 
HaCaT cells using guanidine isothiocyanate  method and reverse  transcribed 
to cDNA. To study the presence of  exon  v6 containing mRNA in these cells, 
primers B and C (see Fig. 2 A) were used for PCR. The PCR products were 
separated in 1.5 % agarose gel, blotted onto nylon membranes (Zeta-Probe, 
BioRad Labs.),  hybridized to a l~2-1abeled  oligonucleotide probe from 
exon v6 (probe G in Fig. 2 A) according  to standard procedures for Southern 
blotting (46). As controls, parallel reactions were performed that contained 
all the reagents except reverse transcriptase. 
Results 
Establishment of the Human Variant  Exon 
v6-Specific Monoclonal Antibody 
Exon v6 has been reported to play a crucial role in the devel- 
opment of metastatic deposits of rat adenocarcinoma cells 
(13).  To  study  the  expression of CD44v6  in  man,  mAbs 
against a  synthetic polypeptide from the exon v6 were pro- 
duced. The hybridomas were screened by using ELISA. Su- 
pernatant from one hybridoma recognized the peptide used 
for immunization, but not a  scrambled version of the same 
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CD44v6.  Hermes-3  reactive 
material was isolated from a 
leukopheresis sample using an 
affinity column,  resolved  in 
SDS-PAGE, and blotted.  Re- 
activity with mAbs Var3.1 and 
Hermes-3 was analyzed using 
immunoperoxidase  method 
(see Materials  and Methods) 
(Lane /) Hermes-3;  0ane 2) 
Var3.1 (lane 3) 3G6 (negative 
control). Arrows point to the 
two major forms of  CD44 rec- 
ognized by mAb Var3.1. Mo- 
lecular weight standards (kD) 
are indicated on the left. 
peptide or another unrelated peptide (Fig.  1). This exon v6 
specific mAb (designated mAb Var3.1) was selected for fur- 
ther studies after subcloning. 
The specificity ofmAb Var3.1 was demonstrated by show- 
ing that it reacted with a recombinant protein containing hu- 
man v6. Since HaCaT cells express several forms of CIM4, 
inclusion of v6 in the construct was ensured by making the 
PCR reaction in two steps (Fig. 2 A). First, variant CD44 
was produced in two reactions in which the primer C  was 
from exon v6 (and both B and C from the sequence that was 
formerly called domain 3, ref. 20) and thus determined the 
specificity of the reaction.  Next,  these two PCR products 
were joined  by  using  primers  from the  constant part  of 
CD44.  The  0.95-kb  PCR  product  was  then  cloned  into 
pGEX-2T expression vector and E.  coli were transformed 
with  the  construct.  After IPTG induction,  proteins  from 
whole bacterial lysates were separated in  SDS-PAGE and 
subjected to Coornassie staining (Fig. 2 B). Bacteria trans- 
formed  with  pGEX-2T-Var  produced  an  IPTG-inducible 
'~60-kD molecule, while pGEX-2T encoded for an inducible 
,~28-kD molecule. Next, whole cell lysates of transformed 
bacteria were subjected to SDS-PAGE and Western blotting 
(Fig. 2  C).  It was found that rnAb Var3.1 reacted with the 
,'-,60-kD fusion protein but not with the product of  the parent 
vector alone.  A  negative control mAb  failed to  stain the 
Figure 4. Tissue distribution of  v6 and Hermes-3 epitope containing forms of  CIM4 
in man. (,4) A tonsil section stained with mAb Var3.1. Positive immunoperoxidase 
reaction is seen in the squamous ceils of surface epithelium. Note the predominant 
staining in mid and upper layers. Lymphocytes are negative. (B) Higher magnifica- 
tion of  tonsil epithelium stained with mAb Vat3.1. (C) Expression of CIM4v6 is het- 
erogeneous on high endothelial venules. Some high endothelial venules are brightly 
positive (black arrowheads), whereas others are negative or weakly positive (white 
arrow). (D) A parallel tonsil section (to A) stained with Hermes-3. This antibody 
also stains all the layers of surface epithelium, but the expression is most prominent 
in the basal layers. Lymphocytes in the lymphatic area are brightly positive. (E) 
Hermes-3 epitope is absent from high endothelial venules (arrowheads pointing to 
the luminal surface), e, surface epithelium;/a, lymphoid area.  Bar, 15/~m. 
Salmi et al. Expression of a Variant CD44 in Man  435 Figure 5. CD44v6 is expressed on the surface of squamous epithe- 
lial ceils. In immunoelectronmicroscopy,  plasma membranes of  the 
squamous epithelial cells in human tonsil stain darkly with mAb 
Var3.1. In most cells, the more superficial surface (short arrows) 
stain more strongly than the basal surface (arrowheads). Desmo- 
somes (long  arrows); nucleus, N. Avidin-biotin  peroxidase  method. 
Bar, 1 #m. 
"~60-kD  molecule.  In  additional experiments,  the  gluta- 
thione-S-transferase carrier was removed from glutathione- 
agarose bound fusion proteins by thrombin cleavage.  The 
released v6-containing fragment was then analyzed  in immu- 
noblotting, mAb Var3.1 reacted with the 33-kD protein con- 
taining v6, whereas control mAbs did not react with this 
molecule (Fig. 2 D). Together, the results of ELISA and fu- 
sion protein assays unambiguously show that mAb Var3.1 
recognizes exon v6 of CD44 in man. 
Immunoblotting analyses of Hermes-3 purified CIM4 an- 
tigen from leukopheresis samples revealed that under non- 
reducing  conditions,  mAb  Var3.1 recognized  two  major 
bands (,,o220 and 300 kD) and one faint bigger band (Fig. 
3).  This experiment shows that mAb Var3.1 recognizes an 
epitope of purified CD44. mAb Hermes-3 stained proteins 
of very variable sizes (70-300 kD) from the purified CD44 
material (Fig. 3). 
Expression of  CD44v6 in Normal Tissues 
Immunoperoxidase staining of frozen sections from normal 
human tissues was performed to study the tissue distribution 
of  CD44v6.  In  the  tonsil,  surface  epithelium  intensely 
stained with mAb Var3.1 (Fig. 4, A and B). Reactivity was 
particularly strong in the mid and upper layers of stratified 
squamous epithelium (upper stratum spinosum and stratum 
granulosum), while cells in the basal layers exhibited fainter 
staining. Reticulated crypt epithelium also stained positively 
with mAb Var3.1.  Tonsillar lymphocytes were practically 
nonreactive with  rnAb  Var3.1, as  were  connective tissue 
components (Fig.  4  A).  In germinal centers,  mAb Var3.1 
faintly reacted with cells of dendritic morphology. Luminal 
surface of some blood vessels,  including high endothelial 
venules, also stained with mAb Var3.1 (Fig. 4  C). In com- 
parison, expression of  the Hermes-3 epitope on tonsillar sur- 
face epithelium was most pronounced basally and notably 
less was seen in upper layers (Fig. 4 D). mAb Hermes-3 in- 
tensely reacted with practically all lymphoeytes outside the 
germinal centers, and fibroblasts were strongly positive in 
Table L  Cell and Tissue Distribution of Var3.1 and 
Hermes-3 Epitopes of CD44 
Var3.1  Hermes-3 
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Blood cells were surface-stained for immunofluorescence and analyzed with 
FACS. Frozen sections of tissues were stained using immunoperoxidase stain- 
ing. Intensity of staining was scored as follows: -,  negative; -/+,  weak; +, 
moderate;  +  +,  strong. HEV, high endothelial venules. 
the septae. On the other hand, endothelial lining of most ves- 
sels and all high endothelial venules was Hermes-3 negative 
(Fig. 4 E). 
In EM, the plasma membrane of the superficial squamous 
cells  stained homogeneously dark in peroxidase prepara- 
tions, and the staining was usually more intense on the su- 
perficial side of the cell (Fig. 5). 
Expression patterns obtained by mAbs Var3.1 and Her- 
mes-3 were clearly distinct in several other tissues in addi- 
tion to tonsil (Table I). In the skin, CD44v6 was preferen- 
tially localized in the upper layers of the epidermis, except 
in keratinized surface layer that was negative. In the dermis, 
fibroblasts and other stromal elements were negative, while 
hair follicles and sweat glands stained positively with mAb 
Var3.1. Expression of  the Hermes-3 epitope in the epidermis 
was most prominent basally, and in the dermis, Hermes-3 
epitope was abundantly present in fibroblasts.  In the intes- 
tine, enteroeytes and dendritic cells of Peyer's patches showed 
weak reactivity with mAb Var3.1, whereas CIM4v6 was ab- 
sent from other structures, mAb Hermes-3 stained entero- 
cytes much more strongly, and the Hermes-3 epitope was 
also present in lymphoid, smooth muscle, and connective 
tissue cells of the gut. CD44v6 was not present on neurons 
or glial cells of  brain white or gray matter. Peripheral nerves 
also lacked this molecule. In contrast, glial cells of white 
matter were intensely positive with rnAb Hermes-3. 
Intraceliular Localization of C1M4v6 in Blood 
Leukocytes and Cell Lines 
CIM4v6 was absent from the surface of PBL, monocytes, 
and granulocytes as determined by FACS-analysis  (Fig. 6). 
The Journal of Cell Biology, Volume 122,  1993  436 Figure 6. Expression of CD44v6 on blood lymphocytes. (A) Fresh PBL (PERM-, left column) do not express CD44v6 on their surface, 
but are Hermes-3 bright. When the cells are permeabilized with 1% formaldehyde and acetone before staining (PERM +, right column), 
many cells become CD44v6 positive, x-axis is relative fluorescence on a log scale; y-axis is cell number. (B) In immunofluorescence  micros- 
copy, permeabilized PBL show intracellular staining for CD44v6, which preferentially is localized in the periphery of cells. (Top) mAb 
3G6 (negative control); (middle) mAb Var3.1; (bottom) mAb Hermes-3. Bar, 10/~m. 
PWM/PHA-induced immunoblasts and plasma cells did not 
express this form of CD44 either. However, when the cells 
were subjected to permeabilization before the immunofluo- 
rescence staining, majority of  both unactivated and activated 
lymphocytes expressed Var3.1 epitope (Fig. 6 A). Number 
of positive cells ranged between 50 and 100% in different in- 
dividuals.  In  fluorescence microscopy, positive  reactivity 
was  preferentially localized in  the periphery of the cells, 
and fainter diffuse staining  was detectable throughout the 
cytoplasm (Fig. 6 B). Existence of CD44v6 in normal PBL 
was confirmed by showing the presence of v6 specific mRNA 
in  these  cells  (Fig.  7).  In  contrast  to  mAb  Var3.1,  the 
Hermes-3 epitope was abundantly expressed on surfaces of 
all human blood leukocyte subtypes as confirmed in FACS 
and immunofluorescence microscopy analyses (Fig.  6). 
We also tested several cultured cell lines for mAb Var3.1 
positivity.  Human keratinocyte (HaCaT),  epithelial  carci- 
noma (HeLa, U1690, A549), and hematopoietic (KG-1, KG- 
la, K562, U937) cell lines all lacked CD44v6 on their sur- 
face.  However,  all  of them  tested  after permeabilization 
(HaCaT, HeLa, U1690) showed clear intracellular staining 
with mAb Var3.1.  Nonspecific "stickiness" of mAb Var3.1 
was ruled out by showing that two carcinoma cell lines (Tera-1 
and T-47D) were negative with this rnAb also intracellularly. 
In  contrast to  CD44v6,  all  cell  lines  (except Tera-1  and 
T-47D) displayed Hermes-3 reactivity both on the cell sur- 
face and in the cytoplasm (data not shown). 
Molecular Form and Detergent Solubility of CD44v6 
Since CD44 is known to associate with cytoskeleton, we de- 
termined whether CD44v6 would also be linked to cytoskel- 
etal  proteins.  Permeabilized HaCaT  cells  were incubated 
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and a squamocellular carcinoma are shown in Fig. 9. All dis- 
tant metastatic lesions of squamocellular carcinomas were 
practically negative with mAb Var3.1. In contrast, Hermes-3 
brightly stained all benign and majority of the malignant cell 
types, including the metastatic deposits, in these specimens 
(Fig. 9). 
Figure 7. v6-specific RNA is present in human PBL. RNA was iso- 
lated from PBL and HaCat cells,  reverse transcribed to cDNA, 
PCR amplified with primers B and C (see Fig. 2 A), separated in 
agarose gel, transferred onto nylon membrane, and hybridized with 
a v6 specific probe (probe G, Fig. 2 A). (Lane/) lymphocytes; (lane 
3) HaCat cells.  Lanes 2  (lymphocyte) and 4 (HaCaT) represent 
negative control reactions which were identical to those seen in 
lanes I and 3 with the exception that no reverse transcriptase was 
added into the cDNA synthesis reaction. 
in PBS with or without 0.5 % nonionic detergent NP-40 and 
stained for immunofluorescence (Fig.  8).  Immunofluores- 
cence microscopy showed that  a  considerable amount of 
CD44v6 was in NP-40 insoluble form. In contrast, signifi- 
cant amount of Hermes-3 containing form of CD44 disap- 
peared during the NP-40 treatment. Similar results were ob- 
tained when PBL were analyzed (data not shown). 
No molecular mass for CD44v6 was obtained from NP-40 
lysates of HaCaT cells in Western blotting or in immuno- 
precipitations after labeling with [35S]methionine,  [35S]cys- 
teine, [35S]sulphate, and [~4C]glucosamine,  probably due to 
the poor NP-40 solubility of CIM4v6 in these cells. More- 
over, mAb Vat3.1  also appears to be a poorly precipitating 
antibody. However, in immunoblotting of SDS solubilized 
HaCaT  cells,  a  faint  ,~200-kD  band  was  seen  (data  not 
shown). 
Downregulation of CD44v6 in Human Neoplasms 
The role of different CD44 forms in spread of malignancies 
is currently under dispute. Therefore, we stained 37 samples 
from  benign  (7  papillomas)  and  malignant  (total  30:5 
metastatic, 5 grade HI, 10 grade 1I and 10 grade I head and 
neck squamous cell carcinomas) epidermal tumors for ex- 
pression  of CD44v6.  These  experiments  showed that  all 
epidermal  cells  in  benign  neoplasms  stained  with  mAb 
Var3.1  like  their normal  counterparts  in  the  neighboring 
healthy tissue. In contrast, expression of CD44v6 was down- 
regulated in all carcinoma samples in the malignant areas. 
In general, better differentiated carcinomas displayed more 
intense mAb Var3.1 reactivity than the more undifferentiated 
Discussion 
Differential Localization of Var3.1 and Hermes-3 
Epitopes of  CD44 
In this paper, we describe production of a novel mAb against 
exon v6 of human CD44. Specificity of this mAb Vat3.1 was 
confirmed by showing that it recognizes (a) a synthetic pep- 
tide from exon v6,  (b) recombinant protein containing v6, 
and (c) isolated CD44 antigen. Anti-CD44 antibodies gener- 
ated so far bind to epitopes on three different clusters of the 
standard lymphocyte form (12, 35). Thus, mAb Var3.1 is the 
first mAb reported that can discriminate CIM4v6 from those 
forms of CD44 that do not possess exon v6 (while revising 
this manuscript,  a  MoAb  17 against  an undefined variant 
exon of CD44 [14] and a polyclonal antibody against v6 [Ref. 
19] have been described), mAb Vat3.1 enabled us to analyze 
the expression of this exon in normal and malignant human 
tissues. CD44v6 was present in different types of epithelial 
cells, dendritic cells, and endothelial cells of blood vessels. 
Most abundant expression was seen in squamous epithelial 
cells, and the Var3.1 epitope appeared to be concentrated on 
the superficial side of the cells. Comparison of the staining 
patterns betweefi mAb Var3.1 and Hermes-3, which binds to 
the constant part of the CD44 molecule, revealed several in- 
teresting features (summarized in Table I). At squamous sur- 
face epithelia, their reactivity profiles were different: mAb 
Var3.1 stained most intensely the cells in the mid and upper 
layers of the epithelium, while the basal layers displayed the 
brightest reactivity with mAb Hermes-3. Connective tissue 
components were strongly reactive with Hermes-3 but did 
not stain with mAb Var3.1. High endothelium of blood ves- 
sels,  on  the  other  hand,  was  mAb  Var3.1-positive,  but 
Hermes-3-negative. CIM4v6 was not present on lymphoid 
cells of secondary lymphatic organs or on the surface of pe- 
ripheral  blood  lymphocytes.  All  these  leukocyte popula- 
tions, however, stained brightly with mAb Hermes-3. Thus, 
the expression of exon v6 is restricted to few specialized cell 
types, whereas Hermes-3 epitope is present on a wide vari- 
ety of cells. 
Hermes-3  negative,  Var3.1  positive phenotype of some 
high  endothelial venules provides evidence that  forms of 
CD44 exist which do not react with mAb Hermes-3. This 
means that new isoforms of CIM4 that do not contain the en- 
tire constant region are likely to be found. Alternatively, this 
finding could be explained by different affinities of mAbs 
Var3.1 and Hermes-3 (highly unlikely on the basis of com- 
parable  staining  intensities)  or by cross-reaction of mAb 
Vat3.1  with some other molecule(s). 
In contrast to the expression on the surface of epithelial 
cells in vivo, peripheral blood leukocytes and several epithe- 
lial cell lines only expressed CD44v6 intracellularly. It ap- 
parentiy distributed both as  a  membrane-associated form 
and diffusely in the cytoplasm. The acetone treatment per se 
The Journal of Cell Biology,  Volume 122, 1993  438 Figure 8. CD44v6 is associated with the cytoskeleton.  Fixed and permeabilized  HaCaT cells were treated without (A-B) or with (C-F) 
0.5%  NP-40 before immunofluorescence  staining with mAb Var3.1 (A and C), Hermes-3 (B and D), and 3G6 (negative control,  E and 
b'). Significant amount of the Var3.1 reactive material was resistant to NP-40 treatment,  while Hermes-3 staining was greatly diminished 
after the treatment.  Bar,  10 #m. 
(used for permeabilization) was not necessary for accessibil- 
ity of Var3.1  epitope to mAb, since mAb Var3.1  stainings 
produced  identical  reaction  patterns  on acetone-fixed and 
nonfixed cryostat sections of tonsil. Therefore, acetone does 
not unmask the Var3.1 epitope by dissolving some lipid con- 
stituents of the cell membrane. We observed that consider- 
able amount of CD44v6 was in an NP-40-insoluble form, 
and thus, it is most probably linked to cytoskeletal proteins. 
The cytoplasmic tail of the standard CIM4 is known to be 
associated with ankyrin,  which  links transmembrane pro- 
teins to actin and fodrin in mouse T-lymphoma cells (31). 
CD44 also colocalizes with vimentin in WI-38 and with ac- 
tin in 3T3 cells (5,  34).  Furthermore, A3D7 and Hermes-1 
(other anti-CIM4 antibodies against the constant part) reac- 
tive material has been shown to exist in the NP-40 insoluble 
form in human T cells (11). Our results suggest that CD44v6 
can,  at least partly, account for these previously described 
detergent insoluble forms of CD44. 
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Squamocellular Tumors in Man 
In tumors, expression of CD44v6 was not altered in benign 
epithelial neoplasms. In contrast, malignant transformation 
was associated to the downregulation of CD44v6.  Impor- 
tantly, the variant CD44v6 was practically absent from the 
metastatic cells. On the other hand, majority of malignan- 
cies remained Hermes-3 positive. These observations hold 
true in the material of 37 epithelial tumors analyzed in this 
work, but these results warrant further studies on the ex- 
pression of  CD44v6 on more cases and on other types of car- 
cinomas.  Our  results  suggest  that  exon v6 would  not be 
responsible for invasive growth and metastasis  formation 
of epithelial squamous  carcinomas.  Rather,  its expression 
seems to be associated with the regulated, normal differenti- 
ation and proliferation of epithelial cells, and its expression 
seems to be silenced during malignant transformation. 
Present results are in agreement with the works reporting 
that the standard lymphocyte form of CD44 is important in 
the invasion and metastasis formation. In a recent study on 
distinct effects of standard  and epithelial  CD44  isoforms 
(containing exons g8-10)  on tumor growth in an  in vivo 
model,  the standard 80-90-kD form, but not the  150-kD 
form, enhanced tumor invasiveness and metastatic activity 
(54). In studies of non-Hodgkin lymphomas, surface expres- 
sion of Hermes-3 correlated positively to the prevalence of 
metastasis (21, 30). Since we were unable to detect exon v6 
on the surface of any leukocyte subset or line, standard form 
is the most likely candidate in mediating the metastatic be- 
havior of non-Hodgkin lymphomas as well.  On the other 
hand, Giinthert et al. found in their rat model that expression 
of the variant form of CD44 on a  rat carcinoma cell line 
resulted  in  the  acquisition  of metastatic  properties  (13). 
Specifically, the rat homologue of human exon v6 was impli- 
cated to have a central role in this process. In this context 
it should be noted that the antibodies against the rat exon v6 
(1.1.ASML, ref. 13, not cross-reactive with human exon v6) 
and against the human exon v6 (Var3.1) should be reactive 
with  the  homologous  or  physically  close  epitopes.  The 
1.1ASML epitope has been mapped within an amino acid se- 
quence of rat exon v6 that only differs by three amino acids 
from the corresponding human peptide in v6 that was used 
for immunization. Very recently, using polyclonal antibody 
against v6, Heider et al. have shown that expression of v6 
is upregulated in precancerous and malignant lesions of hu- 
man colonic epithelium (19). Most likely, the different carci- 
noma material accounts for the majority of the differences 
observed, since we used carcinomas evolving from human 
keratinocytes, while adenocarcinomas were used in other 
studies (13, 19). In fact, our preliminary studies with adeno- 
carcinoma  specimens  indicate that  in  certain cases mAb 
Var3.1 epitope is upregulated during malignant transforma- 
tion.  It has  been  also  reported that  several  alternatively 
spliced large molecular weight variants were overproduced 
in malignant tumors of  breast and colonic tissue in man when 
analyzed by PCR and hybridization (38). Thus, the role of 
CD44 in tumor metastasis may be dependent on the species, 
type of carcinoma, or host microenvironments. 
In conclusion, we have shown that the expression of the 
Var3.1 and Hermes-3 epitope containing forms of CD44 in 
human tissues and cells differs dramatically. Most notably, 
CD44v6 is preferentially epithelial in distribution, intracel- 
lular in lymphoid and epithelial cell lines, and greatly dimin- 
ished or absent in malignant squamous epithelial tumors. 
mAb Var3.1 will offer a possibility to study the regulation of 
expression of a certain form of CD44 during cell differentia- 
tion. It will also prove helpful in dissecting the role of differ- 
ent isoforms in multiple functions of CD44, Finally, it may 
be useful in determining the malignant transformation of epi- 
thelial cells. 
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